Montelukast—An Antileukotriene Treatment for Asthma: Changing the Asthma-Treatment Paradigm

2016 ◽  
pp. 352-371 ◽  
Keyword(s):  
Asthma Treatment ◽  
Treatment Paradigm

Redefining the asthma treatment paradigm using a locally administered dual PI3Kgd inhibitor

2016 ◽  
Author(s):  
Matt Thomas ◽  
Peter Bold ◽  
Karin Bjorhall ◽  
Andrew Butcher ◽  
Johan Carlsson ◽  
...  
Keyword(s):  
Asthma Treatment ◽  
Treatment Paradigm

scholarly journals A Patient Decision Aid for Mild Asthma: Navigating a New Asthma Treatment Paradigm

2021 ◽  
pp. 106568
Author(s):  
Myriam GAGNÉ ◽  
Jeffrey LAM.SHIN. CHEUNG ◽  
Andrew KOURI ◽  
J. Mark FITZGERALD ◽  
Paul M. O’BYRNE ◽  
...  
Keyword(s):  
Decision Aid ◽  
Mild Asthma ◽  
Asthma Treatment ◽  
Patient Decision Aid ◽  
Patient Decision ◽  
Treatment Paradigm

New Asthma Treatment Guidelines

Ob Gyn News ◽  
2005 ◽  
Vol 40 (4) ◽  
pp. 10
Author(s):  
GIDEON KOREN
Keyword(s):  
Treatment Guidelines ◽  
Asthma Treatment

Topical Analgesic Formulations: Following the Transdermal Treatment Paradigm Only?

2019 ◽  
Author(s):  
Jan M Keppel Hesselink
Keyword(s):  
Ad Hoc ◽  
Active Pharmaceutical Ingredient ◽  
Mechanisms Of Action ◽  
Onset Of Action ◽  
Good Tolerability ◽  
Short Commentary ◽  
Topical Analgesics ◽  
The Usa ◽  
Treatment Paradigm ◽  
Topical Analgesic

Topical analgesics are regarded as new inroads to treat peripheral neuropathic pain, with a number of advantages over oral treatments. Topical treatment reduces systemic induced side-effects and have good tolerability, without problems of misuse or abuse, or dependency. Furthermore, the onset of action is fast, mostly within 30 minutes. The mechanism of action of topical analgesics is either via transdermal delivery of the analgesic, or via intradermal mechanisms of action. In the latter case, plasma levels of analgesics in the blood are absent or very low. This perspective is missing in the approach of the ad hoc committee of the National Academies of Sciences, Engineering, and Medicine in the USA, installed by the FDA. In this short commentary, we plead for a more comprehensive approach of topical analgesics, including those formulations which explicitly are not based on transdermal penetration of the active pharmaceutical ingredient, but on intradermal mechanisms of action.

Natural, Synthetic and their Combinatorial Nanocarriers Based Drug Delivery System in the Treatment Paradigm for Wound Healing Via Dermal Targeting

2020 ◽  
Vol 26 (36) ◽  
pp. 4551-4568
Author(s):  
Mohammad Kashif Iqubal ◽  
Sadaf Saleem ◽  
Ashif Iqubal ◽  
Aiswarya Chaudhuri ◽  
Faheem Hyder Pottoo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Wound Healing ◽  
Photodynamic Therapy ◽  
Growth Factors ◽  
Combination Therapy ◽  
Healing Process ◽  
Wound Healing Process ◽  
Wound Site ◽  
Synthetic Drugs ◽  
Treatment Paradigm

A wound refers to the epithelial loss, accompanied by loss of muscle fibers collagen, nerves and bone instigated by surgery, trauma, frictions or by heat. Process of wound healing is a compounded activity of recovering the functional integrity of the damaged tissues. This process is mediated by various cytokines and growth factors usually liberated at the wound site. A plethora of herbal and synthetic drugs, as well as photodynamic therapy, is available to facilitate the process of wound healing. Generally, the systems used for the management of wounds tend to act through covering the ruptured site, reduce pain, inflammation, and prevent the invasion and growth of microorganisms. The available systems are, though, enough to meet these requirements, but the involvement of nanotechnology can ameliorate the performance of these protective coverings. In recent years, nano-based formulations have gained immense popularity among researchers for the wound healing process due to the enhanced benefits they offer over the conventional preparations. Hereupon, this review aims to cover the entire roadmap of wound healing, beginning from the molecular factors involved in the process, the various synthetic and herbal agents, and combination therapy available for the treatment and the current nano-based systems available for delivery through the topical route for wound healing.

Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives

2020 ◽  
Vol 23 (8) ◽  
pp. 687-698 ◽  
Author(s):  
Houda N. Washah ◽  
Elliasu Y. Salifu ◽  
Opeyemi Soremekun ◽  
Ahmed A. Elrashedy ◽  
Geraldene Munsamy ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Therapeutic Potential ◽  
Cell Cancer ◽  
Full Potential ◽  
Future Perspectives ◽  
The Past ◽  
Bioinformatics Tools ◽  
Treatment Paradigm ◽  
Immunotherapy Of Cancer ◽  
Significant Attention

For the past few decades, the mechanisms of immune responses to cancer have been exploited extensively and significant attention has been given into utilizing the therapeutic potential of the immune system. Cancer immunotherapy has been established as a promising innovative treatment for many forms of cancer. Immunotherapy has gained its prominence through various strategies, including cancer vaccines, monoclonal antibodies (mAbs), adoptive T cell cancer therapy, and immune checkpoint therapy. However, the full potential of cancer immunotherapy is yet to be attained. Recent studies have identified the use of bioinformatics tools as a viable option to help transform the treatment paradigm of several tumors by providing a therapeutically efficient method of cataloging, predicting and selecting immunotherapeutic targets, which are known bottlenecks in the application of immunotherapy. Herein, we gave an insightful overview of the types of immunotherapy techniques used currently, their mechanisms of action, and discussed some bioinformatics tools and databases applied in the immunotherapy of cancer. This review also provides some future perspectives in the use of bioinformatics tools for immunotherapy.

scholarly journals Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma

2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
An Uche ◽  
Chad Sila ◽  
Tad Tanoura ◽  
James Yeh ◽  
Neil Bhowmick ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Complete Response ◽  
Heavily Pretreated ◽  
Treatment Paradigm ◽  
Endothelial Growth Factor

Cabozantinib represents an established vascular endothelial growth factor- (VEGF-) tyrosine kinase inhibitor (TKI) in the treatment paradigm of metastatic renal cell carcinoma (mRCC). Its activity in mRCC patients with brain metastases (BMs) has been largely underreported in prospective clinical trials. We present the unique case of a heavily pretreated mRCC patient with BMs who achieved a brain complete response to cabozantinib prior to receiving radiation therapy. We end with a literature review and discussion of the biologic rationale and growing evidence supporting the intracranial activity of cabozantinib.

Sign in / Sign up

Export Citation Format

Share Document